Vertex Pharmaceuticals stock: Revenue rises as outlook is raised
Published on 11/04/2026 at 17:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSVertex broadens growth beyond cystic fibrosis
- Third-quarter revenue growth reflected continued demand for cystic fibrosis therapies and rising contributions from newer medicines.
- Vertex raised its full-year revenue outlook after completing the Crinetics Pharmaceuticals acquisition.
- The November 30 FDA decision on povetacicept could add nephrology as another commercial franchise.
Vertex Pharmaceuticals reported stronger third-quarter sales on Monday, November 2, and raised its full-year revenue outlook as newer medicines expanded the portfolio beyond cystic fibrosis. The company said total revenue for the period ended September 30 increased 12 percent year over year to USD 3.44 billion, according to its third-quarter financial release.
Vertex Pharmaceuticals stock traded at EUR 483.85 on Lang & Schwarz at 17:13:51 CET on Wednesday, November 4, 2026.
New medicines widen the revenue base
Cystic fibrosis remained the core business, with product revenue of USD 3.27 billion compared with USD 3.04 billion a year earlier. ALYFTREK revenue rose to USD 705.8 million from USD 247.0 million, while TRIKAFTA and KAFTRIO revenue declined to USD 2.44 billion from USD 2.65 billion.
Outside the cystic fibrosis portfolio, CASGEVY generated USD 99.2 million in the quarter, JOURNAVX produced USD 58.3 million and PALSONIFY added USD 10.1 million after the Crinetics Pharmaceuticals acquisition closed on September 1. Vertex expects CASGEVY and JOURNAVX to generate at least USD 500 million in combined 2026 revenue.
Higher outlook comes with higher costs
Vertex raised its full-year 2026 revenue guidance to USD 13.15 billion to USD 13.25 billion from USD 13.1 billion to USD 13.2 billion previously. The revised range includes USD 40 million to USD 50 million from PALSONIFY and a foreign-exchange benefit of about 150 basis points.
Reported profitability was weaker because of acquisition-related expenses. GAAP net income fell to USD 653.6 million from USD 1.08 billion, while non-GAAP net income was USD 1.21 billion compared with USD 1.24 billion a year earlier. Vertex also lifted its full-year non-GAAP research and development, acquired in-process research and development, and selling, general and administrative expense outlook to approximately USD 6 billion.
FDA decision sets the next catalyst
The US Food and Drug Administration is conducting a priority review of povetacicept for accelerated approval in immunoglobulin A nephropathy. Vertex said the assigned PDUFA target action date is November 30, 2026. Approval would give the company a commercial entry into nephrology and create another potential growth pillar.
For investors, the results show stronger top-line momentum alongside sizeable spending on launches, the renal franchise and the Crinetics integration. The revenue guidance increase supports the expansion strategy, while execution and launch uptake remain central to the next reporting periods.
Follow the real-time quote of Vertex Pharmaceuticals stock for the latest trading indication.
Broader sentiment for US-listed healthcare companies can be tracked through the S&P 500 market environment.
More news and analyses on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals at a glance
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- Ticker: VRTX
- Primary listing: Nasdaq
- Lang & Schwarz quote: EUR 483.85 at 17:13:51 CET on November 4, 2026
- Third-quarter revenue: USD 3.44 billion, up 12 percent year over year
- 2026 revenue guidance: USD 13.15 billion to USD 13.25 billion
- Next major regulatory date: November 30, 2026, for povetacicept in immunoglobulin A nephropathy
